PR Newswire
MINNEAPOLIS, May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025.
Third Quarter FY2025 Highlights
Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.GAAP earnings per share (EPS) was $0.14 versus $0.31 one year ago. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago.Improved pharma end market conditions, combined with strong commercial execution in Protein Sciences led to 7% organic growth (6% reported) in the segment.Delivered adjusted operating margin of 34.9% (12.2% reported) compared to 33.0% (22.1% reported) in the prior year driven by profitability initiatives and volume leverage.MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Bio-Techne also announced this week that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock. The new share repurchase program begins May 8, 2025 and replaces the previous program. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements. The share repurchase program may be suspended, amended, or discontinued at any time and does not obligate the Company to acquire any specific dollar amount or number of shares of common stock.
ST. PAUL, Minn., May 6, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf, Bio-Techne Corporation and CellReady, today announced that A2 Biotherapeutics, Inc. ("A2") has been awarded a $300,000 G-Rex® Grant. A2's G-Rex® Grant will enable expeditious process development and qualification of a G-Rex-based production system and will enable A2 to evaluate G-Rex for manufacturing cell therapies.
"We are very impressed by the simplicity and scalability of the G-Rex platform and look forward to exploring its applications in our clinical development programs." says Dr. Agi Hamburger, Chief Operating Officer at A2. "As an early-stage company, the G-Rex Grant provides valuable resources to support the process development and comparability studies."
ST. PAUL, Minn., April 29, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March Biosciences has been awarded a $200,000 G-Rex® Grant. March Biosciences' G-Rex® Grant will be used to advance the manufacturing of their lead asset, MB-105, a novel investigational autologous CAR-T cell therapy targeting CD5 for patients with T-cell lymphomas.
"As we ramp up clinical manufacturing and advance towards commercialization of MB-105, scalability continues to be an important focal point. This grant will enable continued development of a robust cGMP process with the G-Rex bioreactor to further reduce complexity, time, and costs incurred with manufacturing autologous CAR-T products," says Dr. Maksim Mamonkin, Chief Scientific Officer at March Biosciences.
New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues
MINNEAPOLIS, April 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of cutting-edge life science tools, today announced an Early Access Program for its latest advancement in spatial biology: a powerful new assay for in situ detection of protein proximity. Built upon Advanced Cell Diagnostics RNAscope™ technology, this next-generation assay is designed to reveal functional interactions between proteins within intact tissues, delivering a spatial solution to explore how molecular signaling shapes disease processes — offering a truly integrated spatial multiomic view.
MINNEAPOLIS, April 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 at McCormick Place Convention Center in Chicago, IL. Bio-Techne's booths will feature its oncology research portfolio spanning early discovery, translational research, and cell and gene therapy development.
AACR is recognized as one of the world's most influential cancer research conferences, convening global experts to exchange groundbreaking discoveries and innovations in cancer science and medicine. Bio-Techne will engage with these researchers and industry professionals to highlight its cutting-edge solutions that empower scientific progress across the oncology landscape.
MINNEAPOLIS, April 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 7, 2025, at 8:00 a.m. CDT to review its third quarter fiscal 2025 financial results.
Access to the discussion may be obtained as follows:
Time:
8:00 a.m. CDT
Date:
May 7, 2025
Dial-in:
1-877-407-9208 or 1-201-493-6784 (for international callers)
Conference ID:
13753150
Webcast:
https://investors.bio-techne.com/ir-calendar
MINNEAPOLIS, April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope™ Multiomic LS Assay and protease-free workflows on Leica's BOND RX research staining instrument, further advancing the capabilities of spatial biology research.
MINNEAPOLIS, March 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region and support the company's long-term regional growth strategy.
The new Customer Experience Centre is scheduled to open in summer 2026 and will feature a state-of-the-art Demonstration Laboratory hosting Bio-Techne's full instrument portfolio, including:
The recently launched Leo™ System, powered by Simple Western™ Technology, which offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.The best-in-class spatial biology platform, COMET™, which is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities.MINNEAPOLIS, March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA. Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will be exhibiting and showcasing RNAscope technology at booth #222.
AmplideX® Nanopore Carrier Plus Kit uses nanopore sequencing to resolve high-prevalence genes.
MINNEAPOLIS and OXFORD, England, March 3, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, has teamed up with Oxford Nanopore Technologies to launch the AmplideX® Nanopore Carrier Plus Kit, a new genetic panel and supporting analysis software for carrier screening research. This innovative kit helps laboratories resolve genes that are challenging to analyze by conventional short-read sequencing and only partially resolved by ancillary assays. The panel is available for research use only.
MINNEAPOLIS, Feb. 20, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with industry-leading sensitivity and specificity, the Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio now includes over 70,000 unique probes across over 450 species.
MINNEAPOLIS, Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based therapies.
The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range of cell types. The new GMP transposase will offer a clearer path to clinic for applications in gene edited cell therapies, such as CAR-T or TCR generation.
MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio techne.com.
MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2024.
Second Quarter FY2025 Highlights
Second quarter organic revenue increased by 9% (9% reported) to $297.0 million.GAAP earnings per share (EPS) was $0.22 versus $0.17 one year ago. Delivered adjusted EPS of $0.42 compared to $0.40 one year ago.Improving biopharma end-market conditions combined with continued momentum of our cell and gene therapy workflow solutions, led to 8% organic growth in our Protein Sciences Segment (7% reported).Strong commercial execution in Diagnostics & Spatial Biology led to 12% organic growth (12% reported) in the segment.MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors.
Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining the faculty at UC Berkeley in 2007, Dr. Herr has served in several university, national, and international leadership roles including as the Founding Executive Director of UC Berkeley's Bakar BioEnginuity Hub – an incubator for academic spin-out companies, and on the National Advisory Council for Biomedical Imaging and Bioengineering (NACBIB) for the National Institutes of Health, as well as governmental science advisory boards. Dr. Herr was a co-founder and advisory board member of Zephyrus Biosciences, which was acquired by Bio-Techne in 2016. Dr. Herr holds a Doctor of Philosophy in Mechanical Engineering from Stanford University and a Bachelor of Science in Engineering & Applied Science from Caltech.
ST. PAUL, Minn., Jan. 21, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that BrainChild Bio has been awarded a $300,000 G-Rex® Grant. The G-Rex® Grant will support expeditious process development and commercial readiness of BCB-276, BrainChild Bio's lead autologous CAR-T therapy for the treatment of diffuse intrinsic pontine glioma (DIPG), an incurable type of pediatric brain tumor. BrainChild Bio plans to advance BCB-276 into a multi-center Phase 2 pivotal clinical trial in 2025 for the treatment of children and young adults with DIPG.
MINNEAPOLIS, Jan. 21, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, February 5, 2025, at 8:00 a.m. CST to review its second quarter fiscal 2025 financial results.
Access to the discussion may be obtained as follows:
Time:
8:00 a.m. CST
Date:
February 5, 2025
Dial-in:
1-877-407-9208 or 1-201-493-6784 (for international callers)
Conference ID:
13751305
Webcast:
https://investors.bio-techne.com/ir-calendar
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.